Core Viewpoint - Southbound funds reduced their holdings in Fosun Pharma (02196.HK) by 118,000 shares on November 21, 2025, while showing a net increase in holdings over the past trading days [1][2]. Group 1: Southbound Fund Activity - Over the last five trading days, southbound funds increased their holdings on four occasions, with a total net increase of 1,302,500 shares [1]. - In the last twenty trading days, there were fifteen days of net increases, totaling 9,318,500 shares [1]. - As of now, southbound funds hold 316 million shares of Fosun Pharma, representing 57.28% of the company's total issued ordinary shares [1][2]. Group 2: Shareholding Changes - On November 21, 2025, the total number of shares held was 316 million, with a decrease of 118,000 shares, reflecting a change of -0.04% [2]. - On November 20, 2025, there was an increase of 194,500 shares, showing a change of 0.06% [2]. - The highest increase in the last five trading days occurred on November 19, 2025, with an addition of 885,500 shares, representing a change of 0.28% [2]. Group 3: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five segments [2]. - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines [2]. - The medical devices and diagnostics segment is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2].